METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE | A204144 | PH HEALTH LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc., et al. 1 patentANDA 204144metformin hydrochloride; sitagliptin phosphate | D. Del. | 2019-02-13 | Terminated 2021-03-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Lachman Consultant Services Inc. - Citizen Petition FDA-2012-P-0826 · 3 docket documents Lachman Consultant Services, Inc., on behalf of a client, filed a petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Sitagliptin and Metformin Hydrochloride Extended-release Tablets, 50 mg/850 mg suitable for consideration in an ANDA, with | Other | 2012-09-06 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.